Active	Status	Sponsor type	Region	Phase	Filter
17 Active 3 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

17 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Crater, Glenn
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Completed	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	08/24	09/24
Stubbs, Richard
NCT05082051: Oral CDX-7108 in Healthy Adults and EPI Subjects	Completed	1	54	RoW	Part A, Single Ascending Dose Study, Part B, Multiple Ascending Dose Study, Part C, Proof-of-Concept Study	Société des Produits Nestlé (SPN)	Exocrine Pancreatic Insufficiency	03/23	03/23
Martinez, Adriana
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis May 2024 - Aug 2024 : Topline data for IPF Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF	Active, not recruiting	3	576	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	06/25	06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis	Recruiting	3	698	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Progressive Pulmonary Fibrosis, Interstitial Lung Disease	11/27	11/27
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
LAPSE, NCT04004702: Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial	Not yet recruiting	2	65	US	Levetiracetam, Keppra	Walter Reed National Military Medical Center	Alzheimer Disease	12/24	06/25
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema	Recruiting	N/A	200	Europe, US, RoW	AeriSeal System	Pulmonx Corporation	Emphysema, Pulmonary, Emphysema or COPD	06/27	03/28
HEAT1, NCT06214780: Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas	Completed	N/A	193	Europe	advanced hybrid closed-loop	Castilla-La Mancha Health Service	Type 1 Diabetes	04/24	05/24
NCT04302272 / 2006-002338-39: STRIVE Post-Market Registry Study	Recruiting	N/A	150	US	Spiration Valve System (SVS)	Olympus Corporation of the Americas	Emphysema	04/25	04/28
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry Oct 2015 - Oct 2015:	Recruiting	N/A	3000	US		Duke University, Boehringer Ingelheim	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	01/28	01/28
Hempfling, Annette
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
Pistenmaa, Carrie L
NCT05567562: Anti-Platelets in Chronic Obstructive Pulmonary Disease	Recruiting	2	30	US	dual anti-platelet therapy, aspirin 81mg EC tab, clopidogrel 75mg tab, Placebo	Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)	COPD, Emphysema, Emphysema or COPD	02/25	06/25
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
Corral, Josie
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis	Recruiting	2	75	US	TTI-101, Placebo	Tvardi Therapeutics, Incorporated	Idiopathic Pulmonary Fibrosis	07/25	07/25
Allegretti, Michael
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
Traux, Brendon
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Crater, Glenn
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Completed	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	08/24	09/24
Stubbs, Richard
NCT05082051: Oral CDX-7108 in Healthy Adults and EPI Subjects	Completed	1	54	RoW	Part A, Single Ascending Dose Study, Part B, Multiple Ascending Dose Study, Part C, Proof-of-Concept Study	Société des Produits Nestlé (SPN)	Exocrine Pancreatic Insufficiency	03/23	03/23
Martinez, Adriana
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis May 2024 - Aug 2024 : Topline data for IPF Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF	Active, not recruiting	3	576	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	06/25	06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis	Recruiting	3	698	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Progressive Pulmonary Fibrosis, Interstitial Lung Disease	11/27	11/27
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
LAPSE, NCT04004702: Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial	Not yet recruiting	2	65	US	Levetiracetam, Keppra	Walter Reed National Military Medical Center	Alzheimer Disease	12/24	06/25
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema	Recruiting	N/A	200	Europe, US, RoW	AeriSeal System	Pulmonx Corporation	Emphysema, Pulmonary, Emphysema or COPD	06/27	03/28
HEAT1, NCT06214780: Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas	Completed	N/A	193	Europe	advanced hybrid closed-loop	Castilla-La Mancha Health Service	Type 1 Diabetes	04/24	05/24
NCT04302272 / 2006-002338-39: STRIVE Post-Market Registry Study	Recruiting	N/A	150	US	Spiration Valve System (SVS)	Olympus Corporation of the Americas	Emphysema	04/25	04/28
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry Oct 2015 - Oct 2015:	Recruiting	N/A	3000	US		Duke University, Boehringer Ingelheim	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	01/28	01/28
Hempfling, Annette
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
Pistenmaa, Carrie L
NCT05567562: Anti-Platelets in Chronic Obstructive Pulmonary Disease	Recruiting	2	30	US	dual anti-platelet therapy, aspirin 81mg EC tab, clopidogrel 75mg tab, Placebo	Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)	COPD, Emphysema, Emphysema or COPD	02/25	06/25
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
Corral, Josie
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis	Recruiting	2	75	US	TTI-101, Placebo	Tvardi Therapeutics, Incorporated	Idiopathic Pulmonary Fibrosis	07/25	07/25
Allegretti, Michael
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
Traux, Brendon
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25